The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Marina Vivarelli,Jonathan Barratt,Laurence H Beck Jr,Fadi Fakhouri,Daniel P Gale,Elena Goicoechea de Jorge,Marta Mosca,Marina Noris,Matthew C Pickering,Katalin Susztak,Joshua M Thurman,Michael Cheung,Jennifer M King,Michel Jadoul,Wolfgang C Winkelmayer,Richard J H Smith,for Conference Participants,Federico Alberici,Luca Antonucci,Tadej Avcin,Arvind Bagga,Ingeborg M Bajema,Miquel Blasco,Sophie Chauvet,H Terence Cook,Paolo Cravedi,Marie-Agnès Dragon-Durey,Lauren Fischer,Agnes B Fogo,Ashley Frazer-Abel,Véronique Frémeaux-Bacchi,Nina Görlich,Mark Haas,Alister Humphreys,Vivekanand Jha,Arenn Jauhal,David Kavanagh,Andreas Kronbichler,Richard A Lafayette,Lynne D Lanning,Mathieu Lemaire,Moglie Le Quintrec,Christoph Licht,Adrian Liew,Steve McAdoo,Nicholas R Medjeral-Thomas,Pier Luigi Meroni,Johann Morelle,Carla M Nester,Manuel Praga,Raja Ramachandran,Heather N Reich,Giuseppe Remuzzi,Santiago Rodríguez de Córdoba,Gary Robinson,Pierre Ronco,Peter Rossing,David J Salant,Sanjeev Sethi,Marianne Silkjaer,Wen-Chao Song,Fabrizio Spoleti,Ronald P Taylor,Nicole C A J van de Kar,Cees van Kooten,Len Woodward,Yuzhou Zhang,Peter F Zipfel,Marco Zuccato

DOI: https://doi.org/10.1016/j.kint.2024.05.015

Abstract:Uncontrolled complement activation can cause or contribute to glomerular injury in multiple kidney diseases. Although complement activation plays a causal role in atypical hemolytic uremic syndrome and C3 glomerulopathy, over the past decade, a rapidly accumulating body of evidence has shown a role for complement activation in multiple other kidney diseases, including diabetic nephropathy and several glomerulonephritides. The number of available complement inhibitor therapies has also increased during the same period. In 2022, Kidney Diseases: Improving Global Outcomes (KDIGO) convened a Controversies Conference, "The Role of Complement in Kidney Disease," to address the expanding role of complement dysregulation in the pathophysiology, diagnosis, and management of various glomerular diseases, diabetic nephropathy, and other forms of hemolytic uremic syndrome. Conference participants reviewed the evidence for complement playing a primary causal or secondary role in progression for several disease states and considered how evidence of complement involvement might inform management. Participating patients with various complement-mediated diseases and caregivers described concerns related to life planning, implications surrounding genetic testing, and the need for inclusive implementation of effective novel therapies into clinical practice. The value of biomarkers in monitoring disease course and the role of the glomerular microenvironment in complement response were examined, and key gaps in knowledge and research priorities were identified.